FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY

S. Zweegman; M. -D. Levin; S. K. Klein; E. G. de Waal; C. M. Eeltink; P. F. Ypma; A. C. Dijk; M. Westerman; W. Deenik; B. Tanis; M. S. Slee-Valentijn; M. C. Minnema; H. Visser-Wisselaar; C. Stege; N. W. van de Donk; K. Nasserinejad; P. Sonneveld

FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY

S. Zweegman, M. -D. Levin, S. K. Klein, E. G. de Waal, C. M. Eeltink, P. F. Ypma, A. C. Dijk, M. Westerman, W. Deenik, B. Tanis, M. S. Slee-Valentijn, M. C. Minnema, H. Visser-Wisselaar, C. Stege, N. W. van de Donk, K. Nasserinejad, P. Sonneveld

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	112-113
Journal	Haematologica
Volume	102
Publication status	Published - 26 Jun 2017

Cite this

Zweegman, S., Levin, M. .-D., Klein, S. K., de Waal, E. G., Eeltink, C. M., Ypma, P. F., Dijk, A. C., Westerman, M., Deenik, W., Tanis, B., Slee-Valentijn, M. S., Minnema, M. C., Visser-Wisselaar, H., Stege, C., van de Donk, N. W., Nasserinejad, K., & Sonneveld, P. (2017). FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY. Haematologica, 102, 112-113.

@article{ec6b15e7f19c4e73ad3f79bd2b26c257,

title = "FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY",

author = "S. Zweegman and Levin, {M. -D.} and Klein, {S. K.} and {de Waal}, {E. G.} and Eeltink, {C. M.} and Ypma, {P. F.} and Dijk, {A. C.} and M. Westerman and W. Deenik and B. Tanis and Slee-Valentijn, {M. S.} and Minnema, {M. C.} and H. Visser-Wisselaar and C. Stege and {van de Donk}, {N. W.} and K. Nasserinejad and P. Sonneveld",

year = "2017",

month = jun,

day = "26",

language = "English",

volume = "102",

pages = "112--113",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

}

Zweegman, S, Levin, M-D, Klein, SK, de Waal, EG, Eeltink, CM, Ypma, PF, Dijk, AC, Westerman, M, Deenik, W, Tanis, B, Slee-Valentijn, MS, Minnema, MC, Visser-Wisselaar, H, Stege, C , van de Donk, NW, Nasserinejad, K & Sonneveld, P 2017, 'FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY', Haematologica, vol. 102, pp. 112-113.

FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY. / Zweegman, S.; Levin, M. -D.; Klein, S. K. et al.
In: Haematologica, Vol. 102, 26.06.2017, p. 112-113.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY

AU - Zweegman, S.

AU - Levin, M. -D.

AU - Klein, S. K.

AU - de Waal, E. G.

AU - Eeltink, C. M.

AU - Ypma, P. F.

AU - Dijk, A. C.

AU - Westerman, M.

AU - Deenik, W.

AU - Tanis, B.

AU - Slee-Valentijn, M. S.

AU - Minnema, M. C.

AU - Visser-Wisselaar, H.

AU - Stege, C.

AU - van de Donk, N. W.

AU - Nasserinejad, K.

AU - Sonneveld, P.

PY - 2017/6/26

Y1 - 2017/6/26

M3 - Meeting Abstract

SN - 0390-6078

VL - 102

SP - 112

EP - 113

JO - Haematologica

JF - Haematologica

ER -